吡格列酮、二甲双胍联用治疗新诊断2型糖尿病的疗效评估

吡格列酮、二甲双胍联用治疗新诊断2型糖尿病的疗效评估

刘慧萍,程丽霞,郭承军

山东省运动康复研究中心内科,山东省潍坊市潍坊人民医院,山东省运动康复研究中心药剂科

收稿日期:2017-08-19 修回日期:2017-09-05 出版日期:2017-09-25
基金资助:
山东省卫计委科研计划项目（项目编号：2015WS0077；项目名称：抗氧化应激联合ARB类药物治疗糖尿病肾病的疗效与改善微炎症进程的相关关系研究）

Therapeutical Evaluation of the Combination of Pioglitazone and Metformin in Treating Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Liu Hui-ping,Cheng Li-xia and Guo Cheng-jun

Dept of InternalMedicine,Shandong Province Sports Rehabilitation Research Center,Wei Fang People Hospital,Weifang,Pharmacy department of Shandong Province Sports Rehabilitation Research Center

Received:2017-08-19 Revised:2017-09-05 Online:2017-09-25

摘要/Abstract

摘要： 目的：评估吡格列酮、二甲双胍联合应用治疗新诊断2型糖尿病的临床效果。方法：选择2016年9月至2017年2月我院收治的40例初诊为2型糖尿病患者作为研究对象，随机分成对照组与观察组，每组各20例，对照组单用二甲双胍治疗，观察组在对照组治疗基础上加用盐酸吡格列酮，经过3个月治疗以后，对比评估两组患者的临床治疗效果。结果：治疗后两组患者的FPG、HbAlc、FINS、HOMA-IR及TC、TG、LDL-C均较治疗前下降、HDL-C升高（P<0.05）；治疗后观察组患者的FPG、HbAlc、FINS、HOMA-IR及TC、TG、LDL-C较对照组明显降低、HDL-C明显升高（P<0.05）。疗效方面，观察组总体有效率显著高于对照组 (P<0.05)。结论：吡格列酮、二甲双胍联用能明显改善２型糖尿病患者糖脂代谢及胰岛素抵抗，且疗效优于单用二甲双胍。

Abstract: Objective：In order to evaluate the clinical effects of the treatment of combination of pioglitazone and metformin in first-visit patients with diagnosed type 2 diabetes mellitus. Methods：40 patients with newly diagnosed type 2 diabetes mellitus in our hospital from September 2016 to February 2017 were included and were randomly divided into the control group and the treatment group with 20 cases in each group.While in the control group，metformin was given and in the treatment group，the combination of metformin and pioglitazone was given for 3 months. Results： FPG， HbAlc， FINS， HOMA-IR， TC， TG， LDL-C were all decreased after treatment in the two groups(P<0.05)， while HDL-C was increased (P<0.05).While FPG， HbAlc， FINS， HOMA-IR， TC， TG， LDL-C in the treatment group were significantly decreased after treatment than that in the control group(P<0.05)，HDL-C was significantly increased(P<0.05).Compared to the therapeutic effect of the control group and the treatment group，the treatment group was significantly higher (P<0.05). Conclusion：Pioglitazone combined with metformin can significantly improve glucose， lipid metabolism and insulin resistance in type 2 diabetes patients，and the effect is better than metformin alone medication.

刘慧萍,程丽霞,郭承军. 吡格列酮、二甲双胍联用治疗新诊断2型糖尿病的疗效评估[J]. .

Liu Hui-ping,Cheng Li-xia and Guo Cheng-jun. Therapeutical Evaluation of the Combination of Pioglitazone and Metformin in Treating Patients with Newly Diagnosed Type 2 Diabetes Mellitus[J]. .

参考文献

[1]张菁，翟迎九，杨燕萍，等．舒洛地特联合辛伐他汀治疗糖尿病下肢血管病变的疗效观察[J]．实用医学杂志，2014，30(15)：2487-2489.
[2]刘佳．人端粒酶反转录酶基因修饰骨髓间充质干细胞静脉移植治疗糖尿病[J]．中国组织工程研究，2015，39(28)：4549-4554.
[3]耿劲松，陈英耀，吴博生．胰岛素注射笔相对于传统注射器治疗糖尿病效果的系统评价[J]．中国全科医学，2014，17(02)：173-176.
[4]Yeh HC,Brown TT,Maruthur N,et al.Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus:a systematic review and meta-analysis[J].Ann Intern Med,2012,157(5):336-347.
[5]Golden SH,Sapir T.Methods for insulin delivery and glucose monitoring in diabetes:summary of a comparative effectiveness review[J].J Manag Care Pharm,2012,18(6 Suppl):S1-17.
[6]王佑民, 杨明功, 刘树琴.长期高血糖对继发磺脲类药物失效患者胰岛B细胞功能的影响[J]中华糖尿病杂志, 2004, 12: 2241.
[7]Foretz M，Hebrard S，Leclerc J，et a1.Metformin inhibits hepatic gluconeogenesis in mice independently of the LKBl／AMPK pathway via a decrease in hepatic energy state．J Clin Invest，2010，120：2355-2369.
[8]Sarabia V，Lam L，Burdett E，et a1．Glucose transport in human skeletal muscle cells in culture．Stimulation by insulin and metformin．J C1in Invest，1992，90：1386-1395.
[9]Zhou G，Myers R，Li Y，et a1．Role of AMP_activated protein kinase in mechanism of metformin action．J Clin Invest，2001，108：1167-1174.
[10]Forslund K，Hildebrand F，Nielsen T，et a1．Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota．Nature，2015，528：262-266.
[11]Hur KY．Lee MS Gutmicrobiota and metabolic disorders．Diabetes Metab J，2015，39：198-203.
[12]0’Moore-Sullivan TM，Prins JB. Thiazolidinediones and type 2 diabetes：New drugs for an old disease[J]．Med J Aust.2002,177(7)：396
[13]刘亚军,侯健红.吡格列酮对2 型糖尿病或糖耐量减低患者内脏脂肪代谢活性影响的观察[J].中国糖尿病杂志,2015,23(2):127-130.
[14]杨华,祁平,吴海清,等.甘精胰岛素联合格列吡嗪与瑞格列奈治疗2型糖尿病的疗效观察[J].中国药房,2011,22(32): 3010-3011.
[15]刘芹,李青,李梦真,等.吡格列酮联合二甲双胍治疗2型糖尿病效果的meta分析[J].上海医药,2014,35(7):29-35，40.
[16]杨士贤，张宝恩，张楠. 吡格列酮合并二甲双胍治疗2型糖尿病的临床疗效[J]. 实用临床医药杂志，2016,20（13）：151-152.
[17]曹梅，董莉，李玉雯，等. 二甲双胍联合吡格列酮对２型糖尿病患者糖脂代谢及胰岛素抵抗的影响[J].医学综述，2016,22（3）：554-556.
[18]郭晶. 吡格列酮联合二甲双胍治疗2 型糖尿病的临床分析[J].系统医学，2017,2（7）：41-43.
[19]王克永，薛丽君，王学武.二甲双胍与吡格列酮联合治疗2型糖尿病的临床观察[J].临床与转化医学，2016,3（7）：43-44.
[20]周梅清，沈云峰，张喜婷.吡格列酮联合二甲双胍对2型糖尿病患者血糖及炎性因子的影响[J].医疗装备，2016,12（29）：30-31.

快速检索引用检索图表检索高级检索